Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 21Active not recruiting 6Recruiting 5Terminated 4Withdrawn 2Suspended 2Not yet recruiting 1

Sponsor Class

OTHER 17INDUSTRY 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Leukemia, Myeloid, Acute 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 11Cyclophosphamide 10Biological Therapy 9Drug Therapy 8Dexamethasone 7Biopsy 7antineoplaston A10 6Nivolumab 6Complementary Therapies 6fludarabine 5antineoplaston AS 2-1 5aldesleukin 5Ipilimumab 5Etoposide 5Doxorubicin 5Cisplatin 5atezolizumab 4Vincristine 4Surgical Procedures, Operative 4Rituximab 4Paclitaxel 4Chemotherapy, Adjuvant 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4venetoclax 3olaparib 3dexamethasone acetate 3dexamethasone 21-phosphate 3copanlisib 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NIH × Azacitidine × Clear all
NCT03745352 2023-06-27

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡